Table 3.
Antimicrobial resistance genes of S. aureus isolates.
| Strain | Antibiotic Resistance Genotype | Antibiotic Resistance Phenotype | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Classa | Genesa | Staphylococcal cassette chromosomeb | MET1 | AMP2 | VA1 | CIP2 | STR1 | TET2 | E2 | GEN2 | TOB2 | LZD2 | CL3 | |
| JE2 | Quinolones β-lactams |
gyrA, grlA
mecA |
SCCmec_type_IVa | R | S | S | R | S | S | S | R | R | S | S |
| SH1000 | - | - | - | S | S | S | I | S | S | S | R | S | S | S |
| MW2 | β-lactams | mecA | SCCmec_type_IVa | R | R | S | I | S | S | S | R | R | S | S |
| 132 | Aminoglycosides Glycopeptides β-lactams Quinolones |
ant(4’)-Ia
bleO mecA gyrA, grlA |
SCCmec_type_IVc | R | S | S | R | S | S | S | R | R | S | S |
| RN4220 | - | - | - | S | S | S | I | S | R | S | R | R | S | S |
| Newman | - | - | - | S | S | S | I | S | S | S | R | R | S | S |
| V329 | - | - | - | S | S | S | I | S | S | S | R | R | S | S |
| Sa9 | - | - | - | S | S | S | I | S | S | S | R | R | S | S |
| Sa5 | - | - | - | S | S | S | I | S | S | S | R | R | S | S |
| Sa7 | β-lactams Aminoglycosides |
blaZ
aph(3’)Ia |
- | S | R | S | I | S | S | S | R | R | S | S |
| IPLA19 | - | - | - | S | S | S | I | S | S | S | S | S | S | S |
| IPLA1 | - | - | - | S | S | S | I | S | R | S | R | R | S | S |
| IPLA3 | β-lactams Tetracycline Aminoglycosides |
mecA, blaZ
tetM, tetK aph(6)-Ic (str) |
SCCmec_type_Vc | R | R | S | I | R | R | S | R | R | S | S |
| IPLA5 | β-lactams | blaZ | S | S | S | I | S | R | S | S | S | S | S | |
| IPLA11 | β-lactams | blaZ | S | R | S | I | S | S | S | S | S | S | S | |
| IPLA13 | - | - | S | S | S | I | S | S | S | S | S | S | S | |
| IPLA15 | β-lactams | blaZ | R | R | S | I | S | S | S | R | R | S | S | |
| IPLA16 | - | - | S | S | S | I | S | S | S | S | S | S | S | |
aβ-lactams (blaZ), amoxicillin; amoxicillin + clavulanic acid; ampicillin; ampicillin + clavulanic acid; cefepime; cefixime; cefotaxime; cefoxitin; ceftazidime; ertapenem; imipenem; meropenem; piperacillin; piperacillin + tazobactam; β-lactams (mecA), methicillin; Aminoglycosides (aph(3’)Ia),neomycin; kanamycin; lividomycin; paromomycin; ribostamycin; gentamicin; Aminoglycosides (ant(4’)-Ia), amikacin/tobramycin/bleomycin; Aminoglycosides (aph(6)-Ic), streptomycin; Quinolones, ciprofloxacin; Tetracyclines, doxycycline; tetracycline; minocycline; Glycopeptides (bleO), bleomycin. Resistance cut-off points, 1Self-established; 2EUCAST breakpoints; 3CLSI breakpoints. MET, Methicillin; AMP, Ampicillin; VA, Vancomycin; CIP, Ciprofloxacin; STR, Streptomycin; TET, Tetraclycline; E, Erythromycin; GEN, Gentamicin; TOB, Tobramycin; LZD, Linezolid; CL, Chloramphenicol.